EN1001
/ Enosi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 24, 2022
"Verse algoritmes en 1001 creatieve oplossingen voor o.a. klimaatproblematiek tijdens #DDW2022 Hieronder slechts wat sfeerbeelden."
(@basaltwoord)
December 08, 2020
"#EnosiLifeSciences Files #Patent for #TNFInhibiting Molecules #EN1001, #EN2001 and #EN3001 https://t.co/rGAq8k45b6"
(@1stOncology)
November 18, 2020
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
(GlobeNewswire)
- "Enosi Life Sciences Corp...announced it has filed a patent for its proprietary molecules. These include EN1001 for autoimmune disease; EN2001 for autoimmune disease and cancer; and EN3001 for autoimmune disease and cancer....The EN1001 molecule blocks Tumor Necrosis Factor Receptor-1 (TNFR1), which is a principal culprit in autoimmune disease, acute inflammation and has a role in cancer."
Patent • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1